Transglutaminase 2 as an Independent Prognostic Marker for Survival of Patients with Non-adenocarcinoma Subtype of Non-small Cell Lung Cancer
Menée in vitro et in vivo, cette étude coréenne (429 cas) évalue l'association entre l'expression de la transglutaminase 2 et la survie de patients atteints d'un cancer du poumon non à petites cellules
BACKGROUND:Expression of transglutaminase 2 (TGase 2) is related to invasion and resistance to chemotherapeutic agents in several cancer cells. However, there has been only limited clinical validation of TGase 2 as an independent prognostic marker in cancer.METHODS:The significance of TGase 2 expression as an invasive/migratory factor was addressed by in vitro assays employing down-regulation of TGase 2. TGase 2 expression as a prognostic indicator was assessed in 429 Korean patients with early-stage non-small cell lung cancer (NSCLC) by immunohistochemical staining.RESULTS:TGase 2 expression increased the invasive and migratory properties of NSCLC cells in vitro, which might be related to the induction of MMP-9. In the analysis of the immunohistochemical staining, TGase 2 expression in tumors was significantly correlated with recurrence in NSCLC (p=0.005) or in the non-adenocarcinoma subtype (p=0.031). Additionally, a multivariate analysis also showed a significant correlation between strong TGase 2 expression and shorter disease-free survival (DFS) in NSCLC (p=0.029 and HR=1.554) and in the non-adenocarcinoma subtype (p=0.030 and HR= 2.184). However, the correlation in the adenocarcinoma subtype was not significant.CONCLUSIONS:TGase 2 expression was significantly correlated with recurrence and shorter DFS in NSCLC, especially in the non-adenocarcinoma subtype including squamous cell carcinoma.
Molecular Cancer , résumé, 2010